Changes in blood ROS, e-NO, and some pro-inflammatory mediators in bronchial secretions following erdosteine or placebo: a controlled study in current smokers with mild COPD.
Anti-oxidant interventions consist in reduction of direct oxidant damage by removing oxidant agents and/or by supplementing reducing agents with anti-oxidant effects.


OBJECTIVE
Aim of the present study was to investigate the anti-oxidant effects of erdosteine, a recent drug currently used in chronic obstructive pulmonary disease (COPD) for its rheological activity. At present, no data are available on current smokers with COPD to our knowledge.


METHODS
Two groups of 10 persons matched for sex; age (65.0 yr+/-8.4 S.D. and 65.3 yr+/-6.5 S.D.); basal FEV1 (88.7% pred +/-6.8 S.D. and 85.2% pred +/-5.8 S.D.); and cigarette consumption (25.4 pack/yr+/-3.5 S.D. and 28.1 pack/yr+/-2.3 S.D.) entered a controlled, double blind, parallel groups study. They were randomized to receive erdosteine 600 mg daily or placebo for 10 days. IL-6; IL-8; TNFalpha were measured in bronchial secretions in bsln, after 4, 7, and 10 days of Erdosteine or placebo; e-NO and both ROS and 8-Isoprostane in blood were also measured at the same experimental times.


METHODS
ANOVA: a t-test with Bonferroni correction; p<0.05 was accepted.


RESULTS
Blood ROS and IL-8 in bronchial secretions dropped significantly following erdosteine starting from day 4 (both p<0.01), while 8-isoprostane drop was significant only after day 10 (p<0.02), and the e-NO decrease proved evident but not significant. No significant changes were observed in the placebo group.


CONCLUSIONS
Erdosteine affects substantially some pro-inflammatory cytokines specifically involved in oxidative stress in current smokers with mild COPD. Effects appeared differently time-dependent. Further long-term studies are needed to confirm these pilot data and to assess their long-term clinical relevance.
Dal Negro
R W
RW
Lung Department, Orlandi General Hospital, Bussolengo, Verona, Italy. uls00030@ulss22.ven.it
Visconti
M
M
Micheletto
C
C
Tognella
S
S
D000368:Aged; D000704:Analysis of Variance; D000975:Antioxidants / Q000494:pharmacology* / Q000627:therapeutic use; D001944:Breath Tests; D001980:Bronchi / Q000187:drug effects* / Q000378:metabolism; D016207:Cytokines / Q000097:blood / Q000378:metabolism*; D015237:Dinoprost / Q000031:analogs & derivatives / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D015850:Interleukin-6 / Q000378:metabolism; D016209:Interleukin-8 / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009569:Nitric Oxide / Q000097:blood*; D029424:Pulmonary Disease, Chronic Obstructive / Q000378:metabolism*; D017382:Reactive Oxygen Species / Q000097:blood*; D012907:Smoking / Q000378:metabolism*; D013864:Thioglycolates / Q000494:pharmacology* / Q000627:therapeutic use; D013876:Thiophenes / Q000494:pharmacology* / Q000627:therapeutic use; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
D000975:Antioxidants; D016207:Cytokines; D015850:Interleukin-6; D016209:Interleukin-8; D017382:Reactive Oxygen Species; D013864:Thioglycolates; D013876:Thiophenes; D014409:Tumor Necrosis Factor-alpha; C075750:8-epi-prostaglandin F2alpha; D009569:Nitric Oxide; C048498:erdosteine; D015237:Dinoprost